Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA accepts NDA filing for Evacet

Feb. 22, 1999

Licensing partner sought for development of prohibitin gene-based cancer Rx, Dx

Feb. 22, 1999

Protein farnesyltransferase inhibitors in development at Bristol-Myers Squibb

Feb. 19, 1999

Genzyme's oncology division in-licenses angiogenesis inhibitor for development

Feb. 19, 1999

Idec Pharmaceuticals announces three new cancer research collaborations

Feb. 19, 1999

CD-437, a novel retinoid compound targeted to the treatment of leukemia

Feb. 18, 1999

Specific inhibitors of MEK for cancer and other proliferative disorders

Feb. 18, 1999

Zarix in-licenses oncology drug from Agouron

Feb. 18, 1999

Initial findings reported for CollaGenex's anticancer compound

Feb. 17, 1999

Wistar Institute discovers mechanism of action of farnesyltransferase inhibitors

Feb. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...